Australia markets close in 5 hours 16 minutes

CSL Limited (CSL.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
280.58+2.78 (+1.00%)
As of 10:24AM AEST. Market open.
Full screen
Previous close277.80
Open276.00
Bid280.44 x 0
Ask280.54 x 0
Day's range276.00 - 280.85
52-week range225.53 - 342.75
Volume123,624
Avg. volume1,099,835
Market cap127.347B
Beta (5Y monthly)0.22
PE ratio (TTM)63.52
EPS (TTM)4.42
Earnings date19 Aug 2020
Forward dividend & yield2.93 (1.04%)
Ex-dividend date11 Mar 2020
1y target est151.95
  • CSL (ASX:CSL) Has Gifted Shareholders With A Fantastic 237% Total Return On Their Investment
    Simply Wall St.

    CSL (ASX:CSL) Has Gifted Shareholders With A Fantastic 237% Total Return On Their Investment

    When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...

  • GlobeNewswire

    uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy

    LEXINGTON, Mass. and AMSTERDAM, June 24, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring with exclusive global rights to etranacogene dezaparvovec, uniQure’s investigational gene therapy for patients with hemophilia B. Etranacogene dezaparvovec consists of an AAV5 viral vector carrying a gene cassette with the patent-protected Padua variant of Factor IX (FIX-Padua). Under the terms of the agreement, uniQure will receive a $450 million upfront cash payment and be eligible to receive up to $1.6 billion in payments based on regulatory and commercial milestones.

  • Thermo Fisher (TMO) Partners With CSL to Expand Pharma Arm
    Zacks

    Thermo Fisher (TMO) Partners With CSL to Expand Pharma Arm

    Thermo Fisher (TMO), through its alliance with CSL, expands Pharma Services arm to meet the rising demand for biologic therapies.